SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

NCT03783416 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis
Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis

Interventions

DRUG: Ixazomib (NINLARO®) capsules / Matching placebo capsules

Sponsor

Queen Mary University of London

Collaborators

[object Object]